Summary of Study ST000401
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000313. The data can be accessed directly via it's Project DOI: 10.21228/M8QG7W This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
Study ID | ST000401 |
Study Title | Inhibition of diamine oxidase promotes uptake of putrescine from rat small intestine |
Study Summary | Metformin, a biguanide molecule, which is used as first line therapy for type 2 diabetes. In this study, we would like to investigate the inhibition of an enzyme called diamine oxidase (DAO) (also known as ABP1), by metformin. Based on our preliminary in vitro study using diamine oxidase enzyme, we saw increased level of putrescine with increasing metformin concentrations (see reference PMID: 26335661). This proposed in vivo study was to determine whether metformin could increase putrescine levels and other metabolites in mice. Aminoguanidine, a known inhibitor of DAO, in this study as positive control, following similar study design described in this paper (PMID: 8912017). |
Institute | University of California, Davis |
Department | Genome and Biomedical Sciences Facility |
Laboratory | WCMC Metabolomics Core |
Last Name | Fiehn |
First Name | Oliver |
Address | 1315 Genome and Biomedical Sciences Facility, 451 Health Sciences Drive, Davis, CA 95616 |
ofiehn@ucdavis.edu | |
Phone | (530) 754-8258 |
Submit Date | 2016-05-16 |
Num Groups | 5 |
Total Subjects | 40 |
Raw Data Available | Yes |
Raw Data File Type(s) | peg |
Analysis Type Detail | GC-MS |
Release Date | 2016-06-18 |
Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Project:
Project ID: | PR000313 |
Project DOI: | doi: 10.21228/M8QG7W |
Project Title: | Inhibition of diamine oxidase promotes uptake of putrescine from rat small intestine |
Project Summary: | Metformin, a biguanide molecule, which is used as first line therapy for type 2 diabetes. In this study, we would like to investigate the inhibition of an enzyme called diamine oxidase (DAO) (also known as ABP1), by metformin. Based on our preliminary in vitro study using diamine oxidase enzyme, we saw increased level of putrescine with increasing metformin concentrations (see reference PMID: 26335661). This proposed in vivo study was to determine whether metformin could increase putrescine levels and other metabolites in mice. Aminoguanidine, a known inhibitor of DAO, in this study as positive control, following similar study design described in this paper (PMID: 8912017). |
Institute: | University of California, Davis |
Department: | Genome and Biomedical Sciences Facility |
Laboratory: | WCMC Metabolomics Core |
Last Name: | Fiehn |
First Name: | Oliver |
Address: | 1315 Genome and Biomedical Sciences Facility, 451 Health Sciences Drive, Davis, CA 95616 |
Email: | ofiehn@ucdavis.edu |
Phone: | (530) 754-8258 |
Funding Source: | NIH U24DK097154 |